Zoledronic acid (ZA) to prevent bone loss during combined androgen blockade with finasteride (CAB+F) for clinically localized or recurrent non-osseous prostate cancer (PC)

S. Tucker,S. Binder Rn,C. Chua Rn,Arthur C. Houts,Barry V. Fortner,Lee S. Schwartzberg

Zoledronic acid (ZA) to prevent bone loss during combined androgen blockade with finasteride (CAB+F) for clinically localized or recurrent non-osseous prostate cancer (PC)

2016

S. Tucker
S. Binder Rn
C. Chua Rn
Arthur C. Houts
Barry V. Fortner
Lee S. Schwartzberg

14628 Background: Androgen suppression (AS) is increasingly used as primary therapy for early PC and recurrent PSA-only PC. AS decreases bone mineral density (BMD), increases markers of osteoclasti...

Keywords:

Bone mineral
Medicine
Androgen
Urology
Prostate cancer
Blockade
Pathology
Primary therapy
Androgen suppression
Finasteride
Zoledronic acid

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations